US2020115457A1PendingUtilityA1
Chimeric receptors and methods of use thereof
Est. expiryApr 1, 2036(~9.7 yrs left)· nominal 20-yr term from priority
C07K 14/7051C12N 15/86C07K 2317/622C12N 2740/15043A61P 1/00A61P 37/06A61P 1/04C07K 14/435A61P 29/00A61P 37/00A61P 21/00C07K 2319/33A61K 2039/505A61P 17/06C07K 16/2851C07K 2317/565C07K 2319/03A61P 35/00C07K 2319/02C07K 14/70521A61P 11/06C07K 14/70517A61P 37/08C07K 2319/30A61P 35/02A61P 19/02A61K 40/31A61K 39/395A61K 40/11A61K 39/0011A61K 38/00
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Antigen binding molecules, chimeric receptors, and engineered immune cells are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the antigen binding molecules and engineered immune cells.
Claims
exact text as granted — not AI-modified1 - 97 . (canceled)
98 . A chimeric antigen receptor that binds to C-type lectin-like-1 (“CLL-1”), wherein the chimeric antigen receptor is a polypeptide comprising a single chain Fv (scFv) that binds CLL-1, a transmembrane domain, and an intracellular activating domain, and wherein the scFv comprises a heavy chain variable region (VH) and light chain variable region (VL) comprising:
(i) a VH region comprising complementarity determining regions (“CDRs”) 1, 2, and 3 with amino acid sequences SEQ ID NO: 95, SEQ ID NO: 52, and SEQ ID NO: 75, respectively; and
(ii) a VL region comprising CDRs 1, 2, and 3 with amino acid sequences SEQ ID NO: 78, SEQ ID NO: 57, and SEQ ID NO: 102, respectively.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.